RESPINOR AS

We are attending #ESICM Congress in Barcelona where RESPINOR DXT clinical evidence study results (DE-RISK WF) will be presented today in the abstract session "Acute respiratory failure 10". To connect, please DM Trude Tingvoll or Marit Mellemseter. We also have DXT available for demonstration. Hope to see you. #diaphragm #monitoring #noninvasivemonitoring #mechanicalventilation #ICU #respiratorycare

The article from the early phase clinical feasibility study with RESPINOR DXT (WEAN-US study) has been published in Critical Care. We are delighted to share these results, which confirm proof of principle and proof of concept for RESPINOR DXT. "The Operator-independent CUSdi quantifies diaphragm excursion and peak velocity similar to standard ultrasound and can reliably predict weaning failure with a defined cut-off value of 1.1 cm, which is consistent with the literature. The technology has a good safety profile as no adverse device effects have been reported. First, it allows the measurement of ultrasound derived indices of diaphragm motion by operators that are not trained for diaphragm ultrasound. Second, these measures can be performed continuously and repeatedly." #MechancialVentilation #Weaning #Diaphragm #Monitoring #NonInvasiveMonitoring #Respiratory #ICU https://lnkd.in/dWcVscwH

#ATS2024 was a busy and highly insightful conference. With Prof Alexandre Demoule, we presented the results from our clinical evidence studies DE-RISK WF, demonstrating that continuous monitoring of the diaphragm with RESPINOR DXT during weaning from mechanical ventilation can identify patients at increased risk of extubation failure. Furthermore, diaphragm dysfunction identified by the RESPINOR DXT is indicative of prolonged ICU and hospital stay. The technology is easy to use and has a good safety profile. By identifying patients at increased risk of reintubation, DXT can contribute to reducing the number of reintubations and, thereby, the risk of severe complications, resulting in improved patient outcomes and a lower resource burden for healthcare professionals and payers. This is a significant step towards our ambition to become the next vital sign for assessing the work of breathing. We want to thank everyone we met at the conference for the great discussions, and we look forward to continuing with existing as well as starting new collaborations in the months to come. #Diaphragm #Monitoring #NonInvasiveMonitoring #ARDS #Respiratory #MechanicalVentilation

We are attending #ATS2024! Our clinical evidence study results (DE-RISK WF) will be presented in a poster discussion session tomorrow, Monday, 2:15 PM - 4:15 PM, by Prof Demoule. B103: Personalizing care for patients with acute respiratory failure To connect, please DM Trude Tingvoll or Marit Mellemseter. We also have RESPINOR DXT available for demonstration. Hope to see you there! #Diaphragm #Monitoring #NonInvasiveMonitoring #ARDS #Respiratory #MechanicalVentilation

RESPINOR has successfully completed the clinical evidence program for the first indication, weaning from mechanical ventilation, and is now preparing for regulatory submission both in Europe and the US. #MedTech #ICU #criticalcare #healthcare #innovationinhealthcare